← Leaderboards
Aruna Das Pradhan
Brigham And Women'S Hospital
$4,705,538
Attributed
$5,149,789
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $877.5K · FY2006–17$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$5,149,789 · 4
By mechanism
R01$4,470,469 · 3
K08$679,320 · 1
Top collaborators
- Yiqing Song2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Julie E Buring$63,823,301
- Joann Elisabeth Manson$50,755,529
- Samia Mora$13,080,456
- Frank M Sacks$39,642,820
- James Kuang-Jan Liao$22,168,806
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationDiabetes MellitusParticipantDoseEvaluationRandomizedGlycosylated Hemoglobin AWomanFollow-UpBaseFundingRisk FactorsCardiovascular SystemEpidemiologic StudiesCostMeasurementCost EffectiveIndexingIntermittent ClaudicationLower ExtremityCardiovascular Risk FactorCardiovascular DiseasesCohortBlood Pressure
Grant awards (15)
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD$355,000
R01 · FY2017 · HL · contact PI
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD$355,000
R01 · FY2016 · HL · contact PI
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD$349,428
R01 · FY2015 · HL · contact PI
Anti-inflammatory Therapy with Low Dose Methotrexate for Reduction of PAD$442,291
R01 · FY2014 · HL · contact PI
Diabetes Prevention in the Vitamin D and Omega-3 Trial$435,185
R01 · FY2014 · DK · contact PI
Diabetes Prevention in the Vitamin D and Omega-3 Trial$453,318
R01 · FY2013 · DK · contact PI
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)$237,768
R01 · FY2013 · HL · contact PI
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)$611,871
R01 · FY2012 · HL · contact PI
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)$612,212
R01 · FY2011 · HL · contact PI
Mechanisms of Statin-Induced DM in JUPITER (Rosuvasatin for CVD Prevention)$618,396
R01 · FY2010 · HL · contact PI
Novel and Traditional Risk Factors for Symptomatic PAD in Women$136,350
K08 · FY2010 · HL · contact PI
Novel and Traditional Risk Factors for Symptomatic PAD in Women$136,350
K08 · FY2009 · HL · contact PI
Novel and Traditional Risk Factors for Symptomatic PAD in Women$136,350
K08 · FY2008 · HL · contact PI
Novel and Traditional Risk Factors for Symptomatic PAD in Women$135,540
K08 · FY2007 · HL · contact PI
Novel/Traditional Risk Factors--Symptomatic PAD in Women$134,730
K08 · FY2006 · HL · contact PI